Table 2 Discounted and undiscounted base case and scenario analysis results, per-patient.
From: Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease
| Â | DT | SOC | |||||
|---|---|---|---|---|---|---|---|
ICERb | Cost | QALY | LY | Cost | QALY | LY | |
Discounted resultsa | |||||||
Base case | $140,877 | $2,372,482 | 26.4 | 29.9 | $1,175,566 | 17.9 | 26.2 |
 Females | $146,511 | $2,377,583 | 26.8 | 30.3 | $1,098,098 | 18.0 | 26.3 |
 Males | $135,574 | $2,367,928 | 26.1 | 29.5 | $1,244,733 | 17.9 | 26.1 |
DT lasts 20-yearsc | $410,607 | $2,761,601 | 21.8 | 27.2 | $1,175,566 | 17.9 | 26.2 |
 Females | $409,161 | $2,703,690 | 22.0 | 27.4 | $1,098,098 | 18.0 | 26.3 |
 Males | $411,937 | $2,813,307 | 21.7 | 27.0 | $1,244,733 | 17.9 | 26.1 |
DT lasts 10-yearsc | $740,058 | $2,914,175 | 20.3 | 26.5 | $1,175,566 | 17.9 | 26.2 |
 Females | $730,453 | $2,836,566 | 20.4 | 26.7 | $1,098,098 | 18.0 | 26.3 |
 Males | $748,848 | $2,983,469 | 20.2 | 26.4 | $1,244,733 | 17.9 | 26.1 |
Undiscounted results | |||||||
Base case | $15,332 | $3,210,182 | 66.2 | 75.8 | $2,770,348 | 37.6 | 54.9 |
 Females | $24,825 | $3,364,554 | 68.5 | 78.9 | $2,607,231 | 38.0 | 55.6 |
 Males | $5,778 | $3,072,350 | 64.2 | 73.0 | $2,915,988 | 37.2 | 54.3 |
DT lasts 20-yearsc | $162,116 | $4,154,316 | 46.1 | 59.6 | $2,770,348 | 37.6 | 54.9 |
 Females | $163,939 | $4,054,067 | 46.8 | 60.7 | $2,607,231 | 38.0 | 55.6 |
 Males | $160,380 | $4,243,825 | 45.4 | 58.7 | $2,915,988 | 37.2 | 54.3 |
DT lasts 10-yearsc | $419,576 | $4,411,570 | 41.5 | 56.3 | $2,770,348 | 37.6 | 54.9 |
 Females | $411,772 | $4,257,316 | 42.0 | 57.1 | $2,607,231 | 38.0 | 55.6 |
 Males | $426,872 | $4,549,296 | 41.0 | 55.6 | $2,915,988 | 37.2 | 54.3 |
